Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 16/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 16/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 15/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 15/20 | 1.00 |
| ▸ | GCGR | P47871 | 13/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 11/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 4/20 | 1.00 |
| ▸ | FRK | P42685 | 4/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | PRKACA | P17612 | 3/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 3/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 2/20 | 1.00 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22170123 | 1.00 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL15075603 | 0.89 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL19868925 | 0.89 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6468970 | 0.88 | MAPK13 (0.79) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6466495 | 0.87 | MAPK13 (0.79) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL1387814 | 0.87 | ALOX5 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6606315 | 0.86 | MAPK11 (0.76) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL14234283 | 0.86 | MAPK11 (0.76) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL2650684 | 0.85 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL4553291 | 0.84 | MAPK14 (0.72) | MAPK11MAPK14MAPK13MAPK12GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | claimed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-6288089-B1 | ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-11 | — | — | US | claimed |
| JP-H09500137-A | — | — | 1997-01-07 | — | — | JP | claimed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | claimed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | claimed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023066735-A1 | GENE THERAPY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022212568-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-3429603-B1 | METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION | CHILDRENS MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | MAPK11 1215/4885MAPK14 662/4885MAPK13 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.